Keywords: AstraZeneca, Merck & Co, Ariad Pharma, Axanum, Ridaforolimus, EU, EMA, CV event prevention, Sarcomas

AstraZeneca gets EU approval for Axanum; Merck & Co files ridaforolimus with EMA

Article | 02 August 2011

Print This

Anglo-Swedish drug major AstraZeneca (LSE: AZN) revealed this morning that it has received approval in 23 European Union member states and ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in